ES2227822T3 - Vehiculo de suministro de genes que expresa las proteinas inductoras de apoptosis vp2 y/o apoptina. - Google Patents

Vehiculo de suministro de genes que expresa las proteinas inductoras de apoptosis vp2 y/o apoptina.

Info

Publication number
ES2227822T3
ES2227822T3 ES98914146T ES98914146T ES2227822T3 ES 2227822 T3 ES2227822 T3 ES 2227822T3 ES 98914146 T ES98914146 T ES 98914146T ES 98914146 T ES98914146 T ES 98914146T ES 2227822 T3 ES2227822 T3 ES 2227822T3
Authority
ES
Spain
Prior art keywords
apoptin
cells
apoptosis
adenovirus
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98914146T
Other languages
English (en)
Spanish (es)
Inventor
Matheus Hubertus Maria Noteborn
Alexandra Maria Pietersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leadd BV
Original Assignee
Leadd BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97201121A external-priority patent/EP0872552A1/fr
Application filed by Leadd BV filed Critical Leadd BV
Application granted granted Critical
Publication of ES2227822T3 publication Critical patent/ES2227822T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
ES98914146T 1997-04-15 1998-04-15 Vehiculo de suministro de genes que expresa las proteinas inductoras de apoptosis vp2 y/o apoptina. Expired - Lifetime ES2227822T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97201121 1997-04-15
EP97201121A EP0872552A1 (fr) 1997-04-15 1997-04-15 Véhicules de transfert de gènes exprimant la protéine VP2 induisant l'apoptose, et/ou l'apoptine
EP97203595A EP0878546A1 (fr) 1997-04-15 1997-11-18 Véhicules de transfert de gènes exprimant la protéine VP2 induisant l'apoptose, et/ou l'apoptine
EP97203595 1997-11-18

Publications (1)

Publication Number Publication Date
ES2227822T3 true ES2227822T3 (es) 2005-04-01

Family

ID=26146368

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98914146T Expired - Lifetime ES2227822T3 (es) 1997-04-15 1998-04-15 Vehiculo de suministro de genes que expresa las proteinas inductoras de apoptosis vp2 y/o apoptina.

Country Status (17)

Country Link
EP (2) EP0878546A1 (fr)
JP (1) JP2001521387A (fr)
KR (1) KR100528755B1 (fr)
AT (1) ATE275200T1 (fr)
AU (1) AU750162B2 (fr)
BR (1) BR9808542A (fr)
CA (1) CA2286165C (fr)
CZ (1) CZ299963B6 (fr)
DE (1) DE69825978T2 (fr)
DK (1) DK0975764T3 (fr)
ES (1) ES2227822T3 (fr)
NO (1) NO994967L (fr)
NZ (1) NZ500012A (fr)
PL (1) PL196607B1 (fr)
PT (1) PT975764E (fr)
SK (1) SK285724B6 (fr)
WO (1) WO1998046760A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9811163A (pt) * 1997-08-12 2000-07-25 Leadd Bv Processos para determinar a capacidade de transformação de um possìvel agente transformador, a predisposição de uma célula em tornar-se uma célula de tumor e de um indivìduo a tipos hereditários de câncer, e uma mutação de gene apresentando atividade oncogênica e/ou transformadora em uma célula, uso de um ácido nucleico codificando apoptina ou um seu fragmento ou derivado funcional, e, kit de teste diagnóstico
AU2004233486B2 (en) * 1999-01-11 2007-09-13 Leadd B.V. Use of apoptosis inducing agents in the treatment of (auto)immune diseases
JP2003500336A (ja) * 1999-01-11 2003-01-07 レアト ベー．フェー． （自己）免疫疾患の治療におけるアポトーシス誘発剤の使用
EP1081226A1 (fr) * 1999-09-02 2001-03-07 Leadd B.V. Protéine liant l' Apoptin
JP2003510030A (ja) * 1999-09-02 2003-03-18 レアト ベー．フェー． アポプチン関連タンパク質
AU784723B2 (en) * 1999-12-10 2006-06-01 Leadd B.V. Apoptin-associating protein
PT1377667E (pt) * 2001-03-30 2009-03-13 Leadd Bv Proteínas de fusão para o tratamento específico de cancro e doenças auto-imunitárias
KR100561985B1 (ko) 2004-07-03 2006-03-22 고려대학교 산학협력단 종양 특이적 아폽틴 발현 카세트 및 이를 포함하는아데노바이러스 발현 벡터
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
CN109111527B (zh) * 2018-08-03 2022-03-15 沈阳金石生物制药有限公司 靶向特异性诱导肿瘤细胞凋亡的gip34-vp3融合蛋白及其制备方法和应用
CN109266714A (zh) * 2018-10-12 2019-01-25 广州医科大学 一种循环肿瘤细胞的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9301272A (nl) * 1993-07-20 1995-02-16 Aesculaap Bv Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus.
NL9002008A (nl) * 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
FR2732348B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel

Also Published As

Publication number Publication date
CZ299963B6 (cs) 2009-01-07
KR20010006460A (ko) 2001-01-26
NO994967L (no) 1999-12-15
DK0975764T3 (da) 2005-01-03
EP0975764A1 (fr) 2000-02-02
WO1998046760A1 (fr) 1998-10-22
AU6856398A (en) 1998-11-11
SK285724B6 (sk) 2007-07-06
CA2286165C (fr) 2009-02-03
ATE275200T1 (de) 2004-09-15
KR100528755B1 (ko) 2005-11-15
CZ349399A3 (cs) 2000-02-16
JP2001521387A (ja) 2001-11-06
DE69825978T2 (de) 2005-09-15
PL196607B1 (pl) 2008-01-31
PL336312A1 (en) 2000-06-19
EP0878546A1 (fr) 1998-11-18
CA2286165A1 (fr) 1998-10-22
EP0975764B1 (fr) 2004-09-01
SK142899A3 (en) 2000-06-12
PT975764E (pt) 2004-11-30
NO994967D0 (no) 1999-10-12
BR9808542A (pt) 2000-05-23
DE69825978D1 (de) 2004-10-07
AU750162B2 (en) 2002-07-11
NZ500012A (en) 2001-04-27

Similar Documents

Publication Publication Date Title
Xu et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein
US7033750B2 (en) Recombinant P53 adenovirus methods and compositions
US5869040A (en) Gene therapy methods and compositions
ES2227822T3 (es) Vehiculo de suministro de genes que expresa las proteinas inductoras de apoptosis vp2 y/o apoptina.
ES2385347T3 (es) Virus con potencia lítica mejorada
Zhuang et al. Differential sensitivity to Ad5 E1B-21kD and Bcl-2 proteins of apoptin-induced versus p53-induced apoptosis
CA2271721A1 (fr) Genes mini-e1a et produits geniques
ES2208942T3 (es) Proteinas e4 de adenovirus para inducir la muerte celular.
ES2200065T3 (es) Utilizacion de apoptina.
US8012925B2 (en) Agent for inducing apoptosis comprising MSX1 or a gene encoding the same as an active ingredient
Schoop et al. Apoptin induces apoptosis in an oral cancer mouse model
US20020187128A1 (en) Novel replication deficient adenovirus vectors and methods for making and using them
US7253150B1 (en) Gene delivery vehicle expressing the aptosis-inducing proteins VP2 and/or apoptin
ES2321485T3 (es) Proteinas de fusion para tratamiento especifico de cancer y de enfermedades autoinmunes.
MXPA99009486A (en) A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin
Rihs et al. Nuclear localization of budgerigar fledgling disease virus capsid protein VP2 is conferred by residues 308–317
KR100241685B1 (ko) 핵산 복합체를 고등 진핵세포내로 도입시키기 위한 조성물
Kaher The Efficient and Specific Tumour Cell Killing by Modified Apoptin
MXPA97009860A (en) Methods and uses for apopt